PHAT
Phathom Pharmaceuticals Inc (PHAT)
Healthcare • NASDAQ • $12.16-0.57%
- Symbol
- PHAT
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $12.16
- Daily Change
- -0.57%
- Market Cap
- $969.83M
- Trailing P/E
- N/A
- Forward P/E
- 8.29
- 52W High
- $18.31
- 52W Low
- $2.82
- Analyst Target
- $23.70
- Dividend Yield
- N/A
- Beta
- 0.57
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Company websiteResearch PHAT on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.